How many drugs treat Chlamydial conjunctivitis?

Drug Landscape tracks 5 marketed treatments for Chlamydial conjunctivitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chlamydial-conjunctivitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chlamydial conjunctivitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chlamydial conjunctivitis (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chlamydial conjunctivitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Azo Gantanol	SULFAMETHOXAZOLE	Pfizer	Sulfonamide Antimicrobial [EPC]		1973-01-01
Azo Gantrisin	sulfafurazole	Alra	Sulfonamide Antimicrobial	Endothelin-1 receptor	1971-01-01
Benzamycin	Erythromycin Lactobionate	Pfizer	Macrolide	Potassium voltage-gated channel subfamily H member 2	1964-01-01
E-Mycin	erythromycin	Generic (originally Abbott/Lilly)	Macrolide [EPC]	Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1	1952-01-01
Klaron	SULFACETAMIDE	Merck & Co.	Sulfonamide Antibacterial	Dihydrofolate reductase	1945-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Chlamydial conjunctivitis
Alra · 1 drug in Chlamydial conjunctivitis
Generic (originally Abbott/Lilly) · 1 drug in Chlamydial conjunctivitis
Merck & Co. · 1 drug in Chlamydial conjunctivitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chlamydial conjunctivitis:

Cite this brief

Drug Landscape (2026). Chlamydial conjunctivitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chlamydial-conjunctivitis. Accessed 2026-06-10.

Chlamydial conjunctivitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing